Immatics (IMTX) Share-based Compensation (2019 - 2023)
Immatics' (IMTX) quarterly Share-based Compensation came in at $6.0 million in Q2 2023, up 1.17% year-on-year from $5.9 million in Q2 2022, and down 8.37% quarter-over-quarter from $6.6 million in Q1 2023.
Immatics (IMTX) Share-based Compensation (2019 - 2023) Analysis & Trends
Immatics has disclosed Share-based Compensation across 5 years of filings, most recently posting $6.0 million for Q2 2023.
- Share-based Compensation for Q2 2023 came in at $6.0 million, up 1.17% year-over-year; the trailing twelve-month figure through Jun 2023 was $24.0 million (changed 0.38% YoY), and the FY2022 annual result was $23.0 million, down 23.76% from the prior year.
- Share-based Compensation came in at $6.0 million for Q2 2023 at Immatics, down from $6.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $10.0 million in Q1 2021 to a low of -$182.1 million in Q4 2020.
- The 5-year median for Share-based Compensation is $5.9 million (2022), against an average of -$17.8 million.
- Across the five-year window, Share-based Compensation slumped 457119.01% in 2020 and jumped 23165.37% in 2021, its largest moves.
- Immatics' Share-based Compensation stood at $39848.0 in 2019, then plunged by 457119.01% to -$182.1 million in 2020, then jumped by 102.97% to $5.4 million in 2021, then rose by 10.16% to $6.0 million in 2022, then advanced by 0.65% to $6.0 million in 2023.
- The last three Share-based Compensation figures came in at $6.0 million (Q2 2023), $6.6 million (Q1 2023), and $6.0 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Dec 31, 2022 | 5.96 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Mar 31, 2022 | 6.40 Mn |
| Dec 31, 2021 | 5.41 Mn |
| Dec 31, 2021 | 5.41 Mn |
| Sep 30, 2021 | 6.37 Mn |
| Sep 30, 2021 | 6.37 Mn |
| Jun 30, 2021 | 9.59 Mn |
| Jun 30, 2021 | 9.59 Mn |
| Mar 31, 2021 | 10.02 Mn |
| Mar 31, 2021 | 10.02 Mn |